Patrick Soon Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X:
“2025 was the unveiling of the Bioshield Platform – Anktiva as foundation for killer cells.
Now for 2026 unveil. Next element to Bioshield Platform – engineered NK cells to TARGET cancer. The CAR-NK in Phase 2 trials infused with Anktiva.
See you at JPM26.”
Title: PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
Authors: Kellsye P Fabian, Michelle R Padget, Renee N Donahue, Kristen Solocinski, Yvette Robbins, Clint T Allen, John H Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James W Hodge
Read the Full Article on Journal for ImmunoTherapy of Cancer
Proceed to the video attached to the post.
More posts featuring Patrick Soon Shiong